Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Spirit Airlines considering bankruptcy filing - WSJ. Port strike ends as dockworkers said to agree on tentative deal with 62% ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...
Bearish investors decided to classify Hims & Hers Health (HIMS) as an obesity drug supplier. HIMS stock lost 9.6% on Thursday after the U.S. Food and Drug Administration said that GLP-1, made by Eli ...
Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform committed to breaking down ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback